5/ Inhaled prostacyclin is effective w/ ILD-PH. Interestingly, same med studied in COPD actually worsened adverse events. Different approaches in these dz. For CTEPH, 1st assess if operative or not, then think abt interventional approach vs riociguat (h…
27a) The measured change in 6MWD from baseline to W 12 with #riociguat up to 2.5 mg TID vs placebo was + 36 m (95% CI, 20 to 52; P<0.001), on the basis of an analysis of the modified #ITT population with missing values imputed 🔓 https://t.co/JgBafZsX…
27b) Yes!--+ 36 m (95% CI, 20 to 52; P<0.001), on the basis of an analysis of the modified #ITT population with missing values imputed (last observed value carried forward or 0 m in case of clinical event) 🔓 https://t.co/DFhQEY5fzC https://t.co/1hawQ6…
41) In the CHEST-1 trial, riociguat improved 6-minute walking distance by 36 meters (36 m; 95% CI, 20 to 52 m) at 12 weeks vs placebo, which led to its approval for #CTEPH. See 🔓https://t.co/DFhQEXNEb2 https://t.co/geX7ulHSoo